Skip to main content

Advertisement

SpringerLink
Log in

Drug development for airway diseases: looking forward

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Advancing drug development for airway diseases beyond the established mechanisms and symptomatic therapies requires redefining the classifications of airway diseases, considering systemic manifestations, developing new tools and encouraging collaborations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vanfleteren, L. E. et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax 69, 72–79 (2014).

    Article  Google Scholar 

  2. Diez, D., Agusti, A. & Wheelock, C. E. Network analysis in the investigation of chronic respiratory diseases. From basics to application. Am. J. Respir. Crit. Care Med. 190, 981–988 (2014).

    Article  Google Scholar 

  3. Agusti, A. et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Am. J. Respir. Crit. Care Med. 191, 391–401 (2014).

    Article  Google Scholar 

  4. Wouters, E. F. et al. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc. Am. Thorac. Soc. 6, 638–647 (2009).

    Article  CAS  Google Scholar 

  5. Jones, P. et al. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 697–709 (2012).

    Article  Google Scholar 

Download references

Acknowledgements

The authors and participants wish to acknowledge A. Martin, P. Pfister and K. Allen at Novartis for their role in facilitating this Respiratory Expert Council.

Author information

Authors and Affiliations

  1. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK

    Stephen Holgate

  2. Thorax Institute, Hospital Clinic, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Barcelona, 08036, Spain

    Alvar Agusti

  3. Novartis Institutes of BioMedical Research, Cambridge, 02139, Massachusetts, USA

    Robert M. Strieter

  4. Department of Pharmacology and Therapeutics, Lung Health Research Centre, University of Melbourne, Melbourne, 3010, Australia

    Gary P. Anderson

  5. Novartis Pharmaceuticals, East Hanover, 07936, New Jersey, USA

    Robert Fogel, Thomas R. Martin & Theodore F. Reiss

  6. Academic Medical Centre, University of Amsterdam, Amsterdam, NL-1105AZ, The Netherlands

    Elisabeth Bel

Authors
  1. Stephen Holgate
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alvar Agusti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert M. Strieter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gary P. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Fogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elisabeth Bel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas R. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Theodore F. Reiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Holgate.

Ethics declarations

Competing interests

Stephen Holgate is Chair of the Novartis Respiratory Council, a non-executive board director of Synairgen and a consultant for AstraZeneca, Regeneron and Amgen.

Robert Fogel, Robert M. Strieter, Theodore F. Reiss and Thomas R. MArtin are employees of Novartis Pharmaceuticals.

Elisabeth Bel serves on advisory boards for GlaxoSmithKline, Novartis and Sanofi.

Gary Anderson serves on advisory boards for Novartis, GlaxoSmithKline, AstraZeneca, Pieris Pharmaceuticals and Boehringer Ingelheim.

Alvar Agusti has received fees for speaking at meetings, participation in advisory boards and/or grant support from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Kyorin, Menarini, Novartis and Takeda.

Supplementary information

Supplementary information S1 (Box)

Members of the Respiratory Expert Council (PDF 119 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holgate, S., Agusti, A., Strieter, R. et al. Drug development for airway diseases: looking forward. Nat Rev Drug Discov 14, 367–368 (2015). https://doi.org/10.1038/nrd4645

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4645

  • Springer Nature Limited

This article is cited by

Search

Navigation